Cullinan Therapeutics is a clinical-stage biotech with no product revenue, evidenced by zero gross margin and operating losses averaging ~$55M per quarter. The pipeline's progress is offset by a deteriorating cash position, with cash falling from $115.0M in 20...
Price trend, volume and key moving averages
Trailing total returns as of 9/24/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q3 2026Latest Aug 6, 2026 | -$0.81-1.3% vs -$0.80 | — vs $4M |
Q2 2026 May 7, 2026 | -$0.75+10.3% vs -$0.84 | — vs $4M |
Q2 2026 Mar 10, 2026 | -$0.77+3.8% vs -$0.80 | — vs $5M |
Q4 2025 Nov 6, 2025 | -$0.77+18.9% vs -$0.95 | — vs $6M |
Engineers Gate Manager LP raised its stake in shares of Cullinan Therapeutics, Inc. (NASDAQ: CGEM) by 130.9% in the undefined quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 153,050 shares of the company's stock after purchasing an additional 86,762 shares during
Cullinan Therapeutics, Inc. (CGEM) Shareholder/Analyst Call Transcript
CAMBRIDGE, Mass., Sept. 14, 2026 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM), a clinical-stage biopharmaceutical company accelerating potential first- or best-in-class, disease-modifying T cell engagers in autoimmune diseases and cancer, today announced that it will host a virtual event for analysts and institutional investors today at 8:00 a.m.
Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd., and Cullinan Therapeutics, Inc. (Nasdaq: CGEM) today announced results from the Phase 3 REZILIENT3 trial e
Benchmark CGEM against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Cullinan Therapeutics, Inc. (CGEM)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $16.87 | $1.04B | -4.53 | — | — | -44.02% | — | |
| $34.54 | $7.13B | -12.47 | — | -7585.86% | -69.59% | — | |
| $115.47 | $9.5B | -31.29 | -16.72% | -285.41% | -21.5% | — | |
| $26.39 | $3.32B | -8.02 | -4.26% | -386.32% | -87.98% | — | |
| $18.09 | $1.03B | -10.52 | 37.22% | -32.54% | -30.62% | — | |
| $0.92 | $14.04M | -0.15 | — | — | -1270.11% | — |
Cullinan Therapeutics, Inc. (CGEM) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Cullinan Therapeutics, Inc. (CGEM) SEC filings — annual & quarterly reports (10-K, 10-Q)
Aug 13, 2026·SEC
Aug 6, 2026·SEC
Jun 16, 2026·SEC
Get notified when CGEM posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Cullinan Therapeutics, Inc. (CGEM) stock FAQ — growth, dividends, profitability & financials explained
Cullinan Therapeutics, Inc. (CGEM) reported a net loss of $204.7M for fiscal year 2025.
Cullinan Therapeutics, Inc. (CGEM) has a return on equity (ROE) of -44.0%. Negative ROE indicates the company is unprofitable.
Cullinan Therapeutics, Inc. (CGEM) had negative free cash flow of $159.3M in fiscal year 2025, likely due to heavy capital investments.
